Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia

  • A. A. Grace
Full Papers

Summary

A unique model of DA system regulation is presented, in which tonic steady-state DA levels in the ECF act to down-regulate the response of the system to pulsatile DA released by DA cell action potential generation. This type of regulation is similar in many respects to the phenomenon proposed to mediate the action of norepinephrine on target neurons; i.e., an increase in the “signal-to-noise” ratio as measured by postsynaptic cell firing (Freedman et al., 1977; Woodward et al., 1979). However, in this model the signal and the noise are neurochemical rather than electrophysiological. Furthermore, the “noise” (tonic DA in the ECF) actually down-regulates the “signal” (phasic DA release) directly, and thereby provides a “signal” of its own that affects the system over a longer time-course. Therefore, the difference between signal and noise may also depend on the time frame under which such determinations are made.

Keywords

Antipsychotic drugs reward nucleus accumbens prefrontal cortex depolarization block basal ganglia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adler M (1961) Changes in sensitivity to amphetamine in rats with chronic brain lesions. J Pharmacol Exp Ther 134: 214–224Google Scholar
  2. Alpert M, Friedhoff AJ, Marcos LR, Diamond F (1978) Paradoxical reactions to L-dopa in schizophrenic patients. Am J Psychiatry 135: 1327–1332Google Scholar
  3. Andén N-E, Fuxe K, Hamberger B, Hökfelt T (1966) A quantitative study of the nigroneostriatal dopamine neuron system in the rat. Acta Physiol Scand 67: 306–312Google Scholar
  4. Angrist BM, Shopsin B, Gershon S (1971) The comparative psychotomimetic effects of stereoisomers of amphetamine. Nature (London) 234: 152–153Google Scholar
  5. Angrist BM, Rotrosen J, Gershon S (1980) Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology 72: 17–19Google Scholar
  6. Baldessarini RJ (1985) Drugs and the treatment of psychiatric disorders. In: Gilman AG, Goodman LS, Rall TW, Murad F (eds) The pharmacological basis of therapeutics, 7th ed. MacMillan, New York, pp 387–445Google Scholar
  7. Beninger RJ (1983) The role of dopamine in locomotor activity and learning. Brain Res Rev 6: 173–196Google Scholar
  8. Benveniste H (1991) Microdialysis — theory and application. In: Gardner E, Nicholson C (eds) Measuring the chemical microenvironment. Society for Neuroscience, Washington DC, pp 54–64Google Scholar
  9. Benveniste H, Hüttemeier PC (1990) Microdialysis — theory and application. Prog Neurobiol 35: 195–215Google Scholar
  10. Bindra D (1978) How adaptive behavior is produced — perceptual-motivational alternative to response reinforcement. Behav Brain Sci 1: 41–52Google Scholar
  11. Blaha CD, Lane RF (1987) Chronic treatment with classical and atypical antipsychotic drugs differentially decreases dopamine release in striatum and nucleus accumbensin vivo. Neurosci Lett 78: 199–204Google Scholar
  12. Bogerts B (1985) Evidence for structural changes in the limbic system in schizophrenia. In: Shagass C, Josiassen RC, Bridger WH, Weiss KJ, Stoff D, Simpson GM (eds) Biological psychiatry. Elsevier, New York, pp 1015–1020Google Scholar
  13. Bogerts B, Meertz E, Schonfeld-Bausch R (1985) Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage. Arch Gen Psychiatry 42: 784–791Google Scholar
  14. Bouyer JJ, Park DH, Joh TH, Pickel VM (1984) Chemical and structural analysis of the relation between cortical inputs and tyrosine hydroxylase-containing terminals in rat neostriatum. Brain Res 302: 267–276Google Scholar
  15. Bunney BS, Aghajanian GK (1976) The precise localization of nigral afferents in the rat as determined by retrograde tracing techniques. Brain Res 117: 423–435Google Scholar
  16. Bunney BS, Grace AA (1978) Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci 23: 1715–1728Google Scholar
  17. Bunney BS, Grace AA (1979) Effects of chronic haloperidol treatment on nigral dopaminergic cell activity. In: Usdin E, Kopin IJ, Barchas J (eds) Catecholamines: basic and clinical frontiers. Pergamon Press, New York, pp 666–668Google Scholar
  18. Bunney BS, Walters JR, Roth RH, Aghajanian GK (1973) Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185: 560–571Google Scholar
  19. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20: 140–144Google Scholar
  20. Carlsson A, Lindqvist M, Magnusson T, Waldeck B (1958) On the presence of 3-hydroxytyramine in brain. Science 127: 471Google Scholar
  21. Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia — implications for schizophrenia and Parkinson's disease. Trends Neurosci 13: 272–276Google Scholar
  22. Chen J, Paredes W, Gardner EL (1991) Chronic treatment with clozapine selectively decreases basal dopamine release in nucleus accumbens but not in caudate-putamen as measured by in vivo brain microdialysis: further evidence for depolarization block. Neurosci Lett 122: 127–131Google Scholar
  23. Chesselet MF, Chéramy A, Romo R, Desban M, Glowinski J (1983) GABA in the thalamic motor nuclei modulates dopamine release from two dopaminergic nigrostriatal pathways in the cat. Exp Brain Res 51: 275–282Google Scholar
  24. Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A 9 and A 10 midbrain dopaminergic neurons. J Neurosci 3: 1607–1619Google Scholar
  25. Chiodo LA, Bunney BS (1985) Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5: 2539–2544Google Scholar
  26. Chiodo LA, Bunney BS (1987) Population response of midbrain dopaminergic neurons to neuroleptics: further studies on time course and nondopaminergic neuronal influences. J Neurosci 7: 629–633Google Scholar
  27. Church WH, Justice JB, Neil DB (1987) Detecting behaviorally relevant changes in extracellular dopamine with microdialysis. Brain Res 412: 397–399Google Scholar
  28. Colle LM, Wise RA (1988) Effects of nucleus accumbens amphetamine on lateral hypothalamic brain stimulation reward. Brain Res 459: 361–368Google Scholar
  29. Connell PH (1958) Amphetamine psychosis. Chapman and Hall, LondonGoogle Scholar
  30. Conrad AJ, Abebe T, Austin R, Forsythe S, Scheibel AB (1991) Hippocampal pyramidal cell disarray in schizophrenia as a bilateral phenomenon. Arch Gen Psychiatry 48: 413–417Google Scholar
  31. Deutch AY, Roth RH (1988) Alterations in dopamine synthesis by chronic neuroleptic administration: a possible biochemical correlate of depolarization inactivation. Soc Neurosci Abstr 14: 27Google Scholar
  32. Doherty MD, Gratton A (1991) Behavioral evidence of depolarization block of mesencephalic dopamine neurons by acute haloperidol in partially 6-hydroxydopamine lesioned rats. Behav Neurosci 105: 579–587Google Scholar
  33. Doucet G, Descarries L, Garcia S (1986) Quantification of the dopamine innervation in adult rat neostriatum. Neuroscience 19: 427–445Google Scholar
  34. Ewing AG, Wightman RM (1984) Monitoring the stimulated release of dopamine within vivo voltammetry. II. Clearance of released dopamine from extracellular fluid. J Neurochem 43: 570–577Google Scholar
  35. Fabre M, Rolls ET, Ashton JP, Williams G (1983) Activity of neurons in the ventral tegmental region of the behaving monkey. Behav Brain Res 9: 213–235Google Scholar
  36. Farnebo L-O, Hamberger B (1971) Drug-induced changes in the release of3 H-monoamines from field-stimulated rat brain slices. Acta Physiol Scand [Suppl] 371: 35–44Google Scholar
  37. Fibiger HC, LePiane FG, Jakubovic A, Phillips AG (1987) The role of dopamine in intracranial self-stimulation of the ventral tegmental area. J Neurosci 7: 3888–3896Google Scholar
  38. Finlay JM, Jakubovic A, Fu DS, Fibiger HC (1987) Tolerance to haloperidol-induced increases in dopamine and metabolites: fact or artifact? Eur J Pharmacol 137: 117–121Google Scholar
  39. Freedman R, Hoffer BJ, Woodward DJ, Puro D (1977) Interaction of norepinephrine with cerebellar activity evoked by mossy and climbing fibers. Exp Neurol 55: 269–288Google Scholar
  40. Freund TF, Powell JF, Smith AD (1984) Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons with particular reference to dendritic spines. Neuroscience 13: 1189–1215Google Scholar
  41. Friedhoff AJ, Miller JC (1983) Clinical implications of receptor sensitivity modification. Annu Rev Neurosci 6: 121–148Google Scholar
  42. Gerfen CR (1984) The neostriatal mosaic: compartmentalization of corticostriatal input and striatonigral output systems. Nature 311: 461–464Google Scholar
  43. Gerlach J, Luhdorf K (1975) The effect of L-DOPA on young patients with simple schizophrenia treated with neuroleptic drugs: a double-blind crossover trial with madopar and placebo. Psychopharmacology 44: 105–110Google Scholar
  44. Glowinski J, Chéramy A, Romo R, Barbeito L (1988) Presynaptic regulation of dopaminergic transmission in the striatum. Cell Mol Neurobiol 8: 7–17Google Scholar
  45. Goldstein JM, Litwin LC (1988) Spontaneous activity of A 9 and A 10 dopamine neurons after acute and chronic administration of the selective dopamine D-1 receptor antagonist SCH 23390. Eur J Pharmacol 155: 175–180Google Scholar
  46. Goldstein JM, Litwin LC, Sutton EB, Malick JB (1989) Effects of ICI 169,369, a selective serotonin2 antagonist, in electrophysiological tests predictive of antipsychotic activity. J Pharmacol Exp Ther 249: 673–680Google Scholar
  47. Gonon FG (1988) Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 24: 19–28Google Scholar
  48. Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41: 1–24Google Scholar
  49. Grace AA, Bunney BS (1980) Effects of baclofen on nigral dopaminergic cell activity following acute and chronic haloperidol treatment. Brain Res Bull 5 [Suppl 2]: 537–543Google Scholar
  50. Grace AA, Bunney BS (1983) Intracellular and extracellular electrophysiology of nigral dopamine neurons. I. Identification and characterization. Neuroscience 10: 301–315Google Scholar
  51. Grace AA, Bunney BS (1984 a) The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci 4: 2866–2876Google Scholar
  52. Grace AA, Bunney BS (1984 b) The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 4: 2877–2890Google Scholar
  53. Grace AA, Bunney BS (1985 a) Opposing effects of striatonigral feedback pathways on midbrain dopamine cell activity. Brain Res 333: 271–284Google Scholar
  54. Grace AA, Bunney BS (1985 b) Low doses of apomorphine elicit two opposing influences on dopamine cell electrophysiology. Brain Res 333: 285–298Google Scholar
  55. Grace AA, Bunney BS (1986) Induction of depolarization block in midbrain dopamine neurons by repeated administration of haloperidol: analysis using in vivo intracellular recording. J Pharmacol Exp Ther 238: 1092–1100Google Scholar
  56. Grace AA, Onn S-P (1989) Morphology and electrophysiological properties of immunocytochemically identified rat dopamine neurons recordedin vitro. J Neurosci 9: 3463–3481Google Scholar
  57. Gratton A, Hoffer BJ, Gerhardt GA (1988) Effects of electrical stimulation of brain reward sites on release of dopamine in rat: an in vivo electrochemical study. Brain Res Bull 21: 319–324Google Scholar
  58. Graybiel AM, Ragsdale CW (1983) Biochemical anatomy of the striatum. In: Emson PC (ed) Chemical neuroanatomy. Raven Press, New York, pp 427–504Google Scholar
  59. Guyenet PG, Aghajanian GK (1978) Antidromic identification of dopaminergic and other output neurons of the rat substantia nigra. Brain Res 150: 69–84Google Scholar
  60. Herrling PL (1985) Pharmacology of the corticocaudate excitatory postsynaptic potential in the cat: evidence for its mediation by quisqualate or kainate receptors. Neuroscience 14: 417–426Google Scholar
  61. Hollerman JR, Grace AA (1989) Acute haloperidol administration induces depolarization block of nigral dopamine neurons in rats after partial dopamine lesions. Neurosci Lett 96: 82–88Google Scholar
  62. Hollerman JR, Abercrombie ED, Grace AA (1992) Electrophysiological, biochemical, and behavioral studies of acute haloperidol-induced depolarization block of nigral dopamine neurons. Neuroscience 47: 589–601Google Scholar
  63. Hornykiewicz O (1963) Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3-hydroxytyramin) in der Substantia nigra des normalen und Parkinsonkranken Menschen. Wien Klin Wochenschr 75: 309–355Google Scholar
  64. Ichikawa J, Meltzer HY (1991) Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens. J Pharmacol Exp Ther 256: 348–357Google Scholar
  65. Imperato I, DiChiara G (1985) Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis. J Neurosci 5: 297–306Google Scholar
  66. Ingvar DH, Franzen G (1974) Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand 50: 425–462Google Scholar
  67. Invernizzi R, Morali F, Pozzi L, Samanin R (1990) Effects of acute and chronic clozapine on dopamine release and metabolism in the striatum and nucleus accumbens of conscious rats. Br J Pharmacol 100: 744–748Google Scholar
  68. Iversen SD (1971) The effect of surgical lesions to frontal cortex and substantia nigra on amphetamine responses in rats. Brain Res 31: 295–311Google Scholar
  69. Jiang LH, Tsai M, Wang RY (1988) Chronic treatment with high doses of haloperidol fails to decrease the time course for the development of depolarization inactivation of midbrain dopamine neurons. Life Sci 43: 75–81Google Scholar
  70. Johnstone E, Crow TJ, Frith CD, Carney MWP, Price JS (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet i: 848–851Google Scholar
  71. Kabzinski AM, Szewczak MR, Cornfeldt ML, Fielding S (1987) Differential effects of dopamine agonists and antagonists on the spontaneous electrical activity of A 9 and A 10 dopamine neurons. Soc Neurosci Abstr 13: 908Google Scholar
  72. Kaplan HI, Sadock BJ (1985) Comprehensive textbook of psychiatry, 4th ed. Williams and Wilkins, BaltimoreGoogle Scholar
  73. Karoum F, Karson CN, Bigelow LB, Lawson WB, Wyatt RJ (1987) Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. Arch Gen Psychiatry 44: 604–607Google Scholar
  74. Kebabian JW, Calne R (1979) Multiple receptors for dopamine. Nature 277: 93–96Google Scholar
  75. Keefe KA, Stricker EM, Zigmond MJ, Abercrombie ED (1990) Environmental stress increases extracellular dopamine in striatum of 6-hydroxydopamine-treated rats: in vivo microdialysis studies. Brain Res 527: 350–353Google Scholar
  76. Keller RW, Duhr WG, Wightman RM, Zigmond MJ (1988) The effects of L-DOPA on in vivo dopamine release from nigrostriatal bundle neurons. Brain Res 447: 191–194Google Scholar
  77. Kiaytkin EA (1988) Functional properties of presumed dopamine-containing and other ventral tegmental area neurons in conscious rats. Int J Neurosci 42: 21–43Google Scholar
  78. Korf J, Venema K (1985) Amino acids in rat striatal dialysates: methodological aspects and changes after electroconvulsive shock. J Neurochem 45: 1341–1348Google Scholar
  79. Kuhr WG, Ewing AG, Caudill WL, Wightman RM (1984) Monitoring the stimulated release of dopamine within vivo voltammetry. I. Characterization of the response observed in the caudate nucleus of the rat. J Neurochem 43: 560–569Google Scholar
  80. Kuhr WG, Wightman RM (1986) Real-time measurement of dopamine release in rat brain. Brain Res 381: 168–171Google Scholar
  81. Lane RF, Blaha CD (1987) Chronic haloperidol decreases dopamine release in striatum and nucleus accumbensin vivo: depolarization block as a possible mechanism of action. Brain Res Bull 18: 135–138Google Scholar
  82. Lehman J, Langer SZ (1983) The striatal cholinergic interneuron: synaptic target of dopaminergic terminals? Neuroscience 10: 1105–1120Google Scholar
  83. Lehmann J, Smith RV, Langer SZ (1983) Stereoisomers of apomorphine differ in affinity and intrinsic activity at presynaptic dopamine receptors modulating [3 H] dopamine and [3 H] acetylcholine release in slices of cat caudate. Eur J Pharmacol 88: 81–88Google Scholar
  84. Lindstrom LH (1985) Low HVA and normal 5-HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history. Psychiatry Res 14: 265–273Google Scholar
  85. Lynch GS, Ballantine P, Campbell BA (1969) Potentiation of behavioral arousal after cortical damage and subsequent recovery. Exp Neurol 23: 195–206Google Scholar
  86. May LJ, Kuhr WG, Wightman RM (1988) Differentiation of dopamine overflow and uptake processes in the extracellular fluid of the rat caudate nucleus with fast-scan in vivo voltammetry. J Neurochem 51: 1060–1069Google Scholar
  87. McGeorge AJ, Faull RLM (1989) The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience 29: 503–537Google Scholar
  88. Meltzer HY (1985) Dopamine and negative symptoms in schizophrenics: critique of the type I-type II hypothesis. In: Alpert M (ed) Controversies in schizophrenia: changes and constancies. Guilford Press, New York, pp 110–136Google Scholar
  89. Meltzer HY, Sommers AA, Luchins DJ (1986) The effects of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Pharmacol 6: 329–338Google Scholar
  90. Meltzer LT, Christoffersen CL, Heffner TG, Freeman AS, Chiodo LA (1989) CI-943, a potential antipsychotic agent. III. Evaluation of effects on dopamine neuronal activity. J Pharmacol Exp Ther 251: 123–130Google Scholar
  91. Miller JD, Sanghera MK, German DC (1981) Mesencephalic dopaminergic unit activity in the behaviorally conditioned rat. Life Sci 29: 1255–1263Google Scholar
  92. Mishra RK, Marshall AM, Varmuza SL (1980) Supersensitivity in rat caudate nucleus: effects of 6-hydroxydopamine on the time course of dopamine receptor and cyclic AMP changes. Brain Res 200: 47–57Google Scholar
  93. Mitchell PR, Doggett NS (1980) Modulation of striatal3 H-glutamic acid release by dopaminergic drugs. Life Sci 26: 2073–2081Google Scholar
  94. Mogenson GJ, Jones DL, Yim CY (1980) From motivation to action: functional interface between limbic system and the motor system. Prog Neurobiol 14: 69–97Google Scholar
  95. Moghaddam B, Gruen RJ (1991) Do endogenous excitatory amino acids influence striatal dopamine release? Brain Res 544: 329–330Google Scholar
  96. Nakahara D, Ozaki N, Kapoor V, Nagatsu T (1989) The effect of uptake inhibition on dopamine release from the nucleus accumbens of rats during self- or forced stimulation of the medial forebrain bundle. A microdialysis study. Neurosci Lett 104: 136–140Google Scholar
  97. Nieoullon A, Chéramy A, Glowinski J (1978) Release of dopamine evoked by electrical stimulation of the motor and visual areas of the cerebral cortex in both caudate nuclei and in the substantia nigra in the cat. Brain Res 145: 69–83Google Scholar
  98. O'Donnell P, Grace AA (1991) Dye-coupling is differentially affected by apomorphine in accumbens core and shell neurons. Soc Neurosci Abstr 17: 456Google Scholar
  99. Olds ME (1990) Enhanced dopamine receptor activation in accumbens and frontal cortex has opposite effects on medial forebrain bundle self-stimulation. Neuroscience 35: 313–325Google Scholar
  100. Onn SP, Berger TW, Grace AA (1991) Dye-coupling in type I and type II striatal neurons: alteration by apomorphine and localization to the patch/matrix. Soc Neurosci Abstr 17: 850Google Scholar
  101. Peroutka SJ, Snyder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, α-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137: 1518–1522Google Scholar
  102. Pettegrew JW, Keshavan M, Panchalingam K (1989)31 P NMR studies in schizophrenia. Biol Psychiatry 25: 15 AGoogle Scholar
  103. Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta M, Allen M (1991) Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. Arch Gen Psychiatry 48: 563–568Google Scholar
  104. Pickar D, Labarca R, Linnoila M, Roy A, Hommer D, Everett D, Paul SM (1984) Neuroleptic-induced decrease in plasma HVA and antipsychotic activity in schizophrenic patients. Science (NY) 225: 954–957Google Scholar
  105. Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, Breier A, Linnoila M, Paul SM (1986) Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Arch Gen Psychiatry 43: 669–676Google Scholar
  106. Pickel VM, Beckley SC, Joh TH, Reis DJ (1981) Ultrastructural immunocytochemical localization of tyrosine hydroxylase in the neostriatum. Brain Res 225: 373–385Google Scholar
  107. Powell EW, Lehman RB (1976) Connections of the nucleus accumbens. Brain Res 105: 389–403Google Scholar
  108. Reimann W, Zumstein A, Starke K (1982) γ-Aminobutyric acid can both inhibit and facilitate dopamine release in the caudate nucleus of the rabbit. J Neurochem 39: 961–969Google Scholar
  109. Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, Casella V, Fowler J, Hoffman E, Alavi A, Som P, Sokoloff L (1979) The (18 F) fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 44: 127–137Google Scholar
  110. Richfield EK, Penney JB, Young AB (1989) Anatomical and affinity state comparisons between dopamine D1 and D2 receptors in the rat central nervous system. Neuroscience 30: 767–777Google Scholar
  111. Roberts GW, Bruton CJ (1990) Notes from the graveyard: neuropathology and schizophrenia. Neuropathol Appl Neurobiol 16: 3–16Google Scholar
  112. Robinson TE, Whishaw IQ (1988) Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res 450: 209–224Google Scholar
  113. Rompré P-P, Wise RA (1989) Behavioral evidence for midbrain dopamine neuron depolarization block. Brain Res 477: 152–156Google Scholar
  114. Rowlands GJ, Roberts PJ (1980) Activation of dopamine receptors inhibits calcium-dependent glutamate release from cortico-striatal terminalsin vitro. Eur J Pharmacol 62: 241–242Google Scholar
  115. Sah P, Hestrin S, Nicoll RA (1989) Tonic activation of NMDA receptors by ambient glutamate enhances excitability of neurons. Science (NY) 246: 815–818Google Scholar
  116. Sands SB, Barish ME (1989) A quantitative description of excitatory amino acid neurotransmitter responses on cultured embryonicXenopus spinal neurons. Brain Res 502: 375–386Google Scholar
  117. Scewczak MR, Dunn RW, Corbett R, Geyer HM, Rush DK, Wilker JC, Strupczewski JT, Helsely GC, Cornfeldt ML (1990) Thein vivo pharmacology of the novel antipsychotic HP 873. Soc Neurosci Abstr 16: 249Google Scholar
  118. Schultz W (1986) Responses of midbrain dopamine neurons to behavioral trigger stimuli in the monkey. J Neurophysiol 56: 1439–1461Google Scholar
  119. Schultz W, Romo R (1990) Dopamine neurons of the monkey midbrain: contingencies of responses to stimuli eliciting immediate behavioral reactions. J Neurophysiol 63: 607–624Google Scholar
  120. Sedvall G, Farde L, Persson A, Weisel FA (1986) Imaging of neurotransmitter receptors in the living human brain. Arch Gen Psychiatry 43: 995–1006Google Scholar
  121. Serrano A, D'Angio M, Scatton B (1989) NMDA antagonists block restraint-induced increase in extracellular DOPAC in rat nucleus accumbens. Eur J Pharmacol 162: 157–166Google Scholar
  122. Sesack SR, Pickel VM (1989) Ultrastructural basis for modulatory interactions between hippocampal and dopaminergic afferents to the rat nucleus accumbens. Soc Neurosci Abstr 15: 1229Google Scholar
  123. Sharp T, Zetterström T, Ungerstedt U (1986) An in vivo study of dopamine release and metabolism in rat brain regions using intracerebral dialysis. J Neurochem 47: 113–122Google Scholar
  124. Shelton RC, Karson CN, Doran AR, Pickar D, Bigelow LB, Weinberger DR (1988) Cerebral structural pathology in schizophrenia: evidence for a selective prefrontal cortical defect. Am J Psychiatry 145: 154–163Google Scholar
  125. Skarsfeldt T (1988) Differential effects after repeated treatment with haloperidol, clozapine, thioridazine, and tefludazine on SNC and VTA dopamine neurons in rats. Life Sci 42: 1037–1044Google Scholar
  126. Skarsfeldt T, Perregaard J (1990) Sertindole, a new neuroleptic with extreme selectivity on A 10 versus A 9 dopamine neurons in the rat. Eur J Pharmacol 182: 613–614Google Scholar
  127. Snyder SH (1972) Catecholamines in the brain are mediators of amphetamine psychosis. Arch Gen Psychiatry 27: 169–179Google Scholar
  128. Sorensen SM, Humphreys TM, Palfreyman MG (1989) Effect of acute and chronic MDL 7314EF, a 5-HT3 receptor antagonist, on A 9 and A 10 dopamine neurons. Eur J Pharmacol 163: 115–118Google Scholar
  129. Stoof JC, Deboer TH, Sminia P, Mulder AH (1982) Stimulation of D-2 dopamine receptors in rat neostriatum inhibits the release of acetylcholine and dopamine but does not affect the release of GABA, glutamate or serotonin. Eur J Pharmacol 84: 211–214Google Scholar
  130. Tamminga CA, Schaffer MH, Smith RC, Davis JM (1978) Schizophrenic symptoms improve with apomorphine. Science 200: 567–568Google Scholar
  131. Tamminga CA, Kaneda H, Buchanan R, Kirkpatrick B, Thaker GK, Yablinski MB, Holcomb HH (1991) The limbic system in schizophrenia. Pharmacologic and metabolic evidence. In: Tamminga CA, Schulz SC (eds) Advances in neuropsychiatry and psychopharmacology, vol 1. Schizophrenia research. Raven Press, New York, pp 99–109Google Scholar
  132. Totterdell S, Smith AD (1989) Convergence of hippocampal and dopaminergic input onto identified neurons in the nucleus accumbens of the rat. J Chem Neuroanat 2: 285–298Google Scholar
  133. Van Kammen DP, Mann LS, Sternberg DE, Scheinin M, Ninan PT, Marder SR, Van Kammen WB, Reider RO, Linnoila M (1983) Dopamine-β-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenic with brain atrophy. Science 220: 974–977Google Scholar
  134. Van Kammen DP, Van Kammen WB, Mann LS, Seppala T, Linnoila M (1986) Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Arch Gen Psychiatry 43: 978–983Google Scholar
  135. Van Rossum JM (1966) The significance of dopamine-receptor blockade for the actions of neuroleptic drugs. Arch Int Pharmacodyn Thér 160: 492–494Google Scholar
  136. Weinberger DR, Berman KF, Zec RF (1986) Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. Arch Gen Psychiatry 43: 114–124Google Scholar
  137. White FJ, Wang RY (1983 a) Comparison of the effects of chronic haloperidol treatment on A 9 and A 10 dopamine neurons in the rat. Life Sci 32: 983–993Google Scholar
  138. White FJ, Wang RY (1983 b) Differential effects of classical and atypical antipsychotic drugs on A 9 and A 10 dopamine neurons. Science (NY) 221: 1054–1057Google Scholar
  139. Williamson P, Drost D, Stanley J, Carr T, Morrison S, Merskey H (1991) Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. Arch Gen Psychiatry 48: 578Google Scholar
  140. Woodward DJ, Moises HC, Waterhouse BD, Hoffer BJ, Freedman R (1979) Modulatory actions of norepinephrine in the central nervous system. Fed Proc 38: 2109–2116Google Scholar
  141. Wyatt RJ (1986) The dopamine hypothesis: variations on a theme (II). Psychopharmacol Bull 22: 923–927Google Scholar
  142. Yim CY, Mogenson GJ (1982) Response of nucleus accumbens neurons to amygdala stimulation and its modification by dopamine. Brain Res 239: 401Google Scholar
  143. Zetterström T, Sharp T, Ungerstedt U (1984) Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis. Eur J Pharmacol 106: 27–37Google Scholar
  144. Zigmond MJ, Berger TW, Grace AA, Stricker EM (1989) Compensatory responses to nigrostriatal bundle injury: studies with 6-hydroxydopamine in an animal model of Parkinsonism. Mol Chem Neuropathol 10: 185–200Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • A. A. Grace
    • 1
  1. 1.Departments of Behavioral Neuroscience and Psychiatry, Center for NeuroscienceUniversity of PittsburghPittsburghUSA

Personalised recommendations